Scemblix (Asciminib)

Scemblix is a kinase inhibitor used for the treatment of adult patients with: Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs). Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation. 

Recommended Dosage: The recommended dosage in Ph+ CML in CP is 80 mg orally taken once daily or 40 mg twice daily and in Ph+ CML in CP with the T315I Mutation is 200 mg taken orally twice daily. Avoid food consumption for at least 2 hours before and 1 hour after taking the scemblix tablets. Swallow tablets of Scemblix whole, without breaking, crushing, or chewing.

• Neutropenia, thrombocytopenia, and anemia have emerged in patients receiving Asciminib. Complete blood counts need to be performed every 14 days for the first 3 months of treatment and monthly thereafter. Assess patients for signs/symptoms of myelosuppression.
• Assess serum lipase and amylase levels monthly during therapy with Scemblix 20mg / 40mg. Assess patients for signs/symptoms of pancreatic toxicity. More frequent monitoring needs to be performed in patients with a history of pancreatitis.

• Hypertension appeared in patients with asciminib treatment. Monitor and manage hypertension using standard antihypertensive therapy during treatment with asciminib; for Grade 3 or higher hypertension, temporarily withhold, reduce dose, or permanently discontinue therapy depending on persistence of hypertension. 
• Hypersensitivity appeared in patients receiving Scemblix 40mg / 20mg. Monitor patients for signs and symptoms of hypersensitivity and initiate apt treatment; for Grade 3 or higher hypersensitivity, temporarily withhold, reduce dose, or permanently discontinue therapy on behalf of persistence of hypersensitivity. 
• Cardiovascular toxicity (including arterial thrombotic, embolic conditions, ischemic cardiac and CNS conditions) and cardiac failure occurred in patients taking therapy with Scemblix. Assess patients with a history of cardiovascular risk factors for cardiovascular signs/symptoms. 
• Depending on findings and its mechanism of action, asciminib can cause fetal harm if administered to a pregnant woman. Verify the pregnancy status of females of reproductive age prior to starting treatment with Asciminib.

Urgent Meds is able to source the SCEMBLIX (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Urgent Meds is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.